IL253775D0 - נוגדנים בעלי שרשרת קלה מהונדסת היסטידין ובעלי חיים לא אנושיים שעברו שינוי גנטי להכנתם - Google Patents

נוגדנים בעלי שרשרת קלה מהונדסת היסטידין ובעלי חיים לא אנושיים שעברו שינוי גנטי להכנתם

Info

Publication number
IL253775D0
IL253775D0 IL253775A IL25377517A IL253775D0 IL 253775 D0 IL253775 D0 IL 253775D0 IL 253775 A IL253775 A IL 253775A IL 25377517 A IL25377517 A IL 25377517A IL 253775 D0 IL253775 D0 IL 253775D0
Authority
IL
Israel
Prior art keywords
חיים
בעלי
נוגדנים
אנושיים
לא
Prior art date
Application number
IL253775A
Other languages
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261611950P priority Critical
Priority to US201261736930P priority
Priority to PCT/US2013/031823 priority patent/WO2013138680A1/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL253775D0 publication Critical patent/IL253775D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Humanized animals, e.g. knockin
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/20Pseudochromosomes, minichrosomosomes
    • C12N2800/204Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
IL253775A 2012-03-16 2017-08-01 נוגדנים בעלי שרשרת קלה מהונדסת היסטידין ובעלי חיים לא אנושיים שעברו שינוי גנטי להכנתם IL253775D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201261611950P true 2012-03-16 2012-03-16
US201261736930P true 2012-12-13 2012-12-13
PCT/US2013/031823 WO2013138680A1 (en) 2012-03-16 2013-03-15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

Publications (1)

Publication Number Publication Date
IL253775D0 true IL253775D0 (en) 2017-09-28

Family

ID=48045078

Family Applications (3)

Application Number Title Priority Date Filing Date
IL234355A IL234355A (en) 2012-03-16 2014-08-28 Genetically modified non-human animals for generating histidine engineered light chain antibodies
IL244097A IL244097A (en) 2012-03-16 2016-02-10 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
IL253775A IL253775D0 (en) 2012-03-16 2017-08-01 נוגדנים בעלי שרשרת קלה מהונדסת היסטידין ובעלי חיים לא אנושיים שעברו שינוי גנטי להכנתם

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL234355A IL234355A (en) 2012-03-16 2014-08-28 Genetically modified non-human animals for generating histidine engineered light chain antibodies
IL244097A IL244097A (en) 2012-03-16 2016-02-10 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

Country Status (25)

Country Link
US (3) US9334334B2 (en)
EP (3) EP2883449B1 (en)
JP (3) JP6185978B2 (en)
KR (1) KR20140135193A (en)
CN (3) CN104302169B (en)
AU (3) AU2013204579B2 (en)
BR (1) BR112014022850A2 (en)
CA (1) CA2865643A1 (en)
CY (2) CY1120599T1 (en)
DK (2) DK2883449T3 (en)
ES (2) ES2679369T3 (en)
HK (2) HK1200273A1 (en)
HR (2) HRP20180682T1 (en)
HU (2) HUE037659T2 (en)
IL (3) IL234355A (en)
LT (2) LT2825036T (en)
MX (1) MX355732B (en)
NZ (1) NZ629639A (en)
PL (2) PL2825036T3 (en)
PT (2) PT2825036T (en)
RS (2) RS57414B1 (en)
RU (2) RU2644684C2 (en)
SG (2) SG11201405165UA (en)
SI (2) SI2883449T1 (en)
WO (1) WO2013138680A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2202245T3 (en) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
BRPI0911431A2 (en) 2008-04-11 2015-10-06 Chugai Pharmaceutical Co Ltd antigen binding method that repeatedly bind to various antigen molecules
RU2603090C2 (en) 2011-10-17 2016-11-20 Регенерон Фармасьютикалс, Инк. Restricted immunoglobulin heavy chain mice
RU2664473C2 (en) 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MX355105B (en) 2013-02-20 2018-04-05 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences.
JP2017521404A (en) 2014-06-30 2017-08-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Anti-TNFa antibody showing pH-dependent antigen binding
RU2017123731A3 (en) 2014-12-19 2019-12-02
SG11201607165YA (en) * 2014-12-19 2016-09-29 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
KR20170110129A (en) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use
CN107614014A (en) * 2015-05-28 2018-01-19 生物辐射实验室股份有限公司 Affinity ligand and its correlation technique
KR101820637B1 (en) * 2015-12-18 2018-01-19 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201891410A1 (en) * 2015-12-18 2019-01-31 Чугаи Сейяку Кабусики Кайся Antibodies to c5 and methods of their application
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
CA3026088A1 (en) 2016-06-03 2017-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
WO2019241692A1 (en) 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991012023A2 (en) 1990-02-16 1991-08-22 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5999908A (en) 1992-08-06 1999-12-07 Abelow; Daniel H. Customer-based product design module
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
TR199902553T2 (en) 1997-04-14 2000-03-21 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Described is a method for the production of an anti human body.
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
WO1999018212A1 (en) 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6946548B2 (en) 2000-09-08 2005-09-20 Massachusetts Institute Of Technology G-CSF analog compositions and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
ES2645563T3 (en) 2001-11-30 2017-12-05 Amgen Fremont Inc. Transgenic animals that carry human Ig light chain genes
EP1511861A4 (en) 2002-06-12 2007-12-05 Genencor Int Methods and compositions for milieu-dependent binding of a targeted agent to a target
JP4836451B2 (en) 2002-07-18 2011-12-14 メルス ベー ヴェー Recombinant production of antibody mixtures
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
DE602004021095D1 (en) 2003-01-21 2009-06-25 Chugai Pharmaceutical Co Ltd Method of screening the light chain of an antibody
ES2408582T3 (en) 2003-05-30 2013-06-21 Merus B.V. Fab library for the preparation of a mixture of antibodies
CN1560081A (en) 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 Preparing human source monoclone antibody by mouse capable of producing human IgGl weight chain-k light chain and application thereof
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
ES2463476T3 (en) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Method to generate a homozygous mouse for a genetic modification
KR20070090890A (en) 2004-10-22 2007-09-06 메디뮨 인코포레이티드 High affinity antibodies against hmgb1 and methods of use thereof
AU2006242854A1 (en) 2005-04-29 2006-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
EP2314619A1 (en) 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2374818T3 (en) 2006-06-02 2013-01-21 Regeneron Pharma High affinity antibodies to human IL-6 receptor
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
RU2445318C2 (en) 2006-10-02 2012-03-20 Ридженерон Фармасьютикалз, Инк. High-affinity human il-4 receptor antibodies
RU2448979C2 (en) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
EP2583551A1 (en) 2007-03-13 2013-04-24 National Jewish Health Methods for generation of antibodies
ITMI20071522A1 (en) 2007-07-27 2009-01-28 Areta Internat S R L idiotypic vaccine
CA2964398A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
PL2202245T3 (en) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
BRPI0911431A2 (en) 2008-04-11 2015-10-06 Chugai Pharmaceutical Co Ltd antigen binding method that repeatedly bind to various antigen molecules
WO2009139822A1 (en) * 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
RS53146B (en) 2008-06-27 2014-06-30 Merus B.V. Antibody producing non-human mammals
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
NZ592308A (en) 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
LT2358756T (en) 2008-12-15 2017-03-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to pcsk9
US20110314563A1 (en) 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
CN102427978B (en) 2009-05-07 2016-01-20 沃尔沃建筑设备公司 Construction machinery and equipment and the method for operating construction machinery and equipment
SG176868A1 (en) 2009-06-26 2012-02-28 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
NZ597481A (en) 2009-07-08 2013-10-25 Kymab Ltd Animal models and therapeutic molecules
AU2010271586B2 (en) 2009-07-16 2016-08-11 Wageningen Universiteit Regulation of zinc deficiency and tolerance in plants
PL2509409T3 (en) 2009-12-10 2017-02-28 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
NZ631363A (en) 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
AU2013271737A1 (en) 2012-06-05 2015-01-22 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
JP2015509380A (en) 2012-03-06 2015-03-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Common light chain mice
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
MX2012010481A (en) 2010-03-11 2012-10-09 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING.
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
ES2575223T3 (en) 2010-06-22 2016-06-27 Regeneron Pharmaceuticals, Inc. Mice expressing a light chain with the human lambda variable and mouse constant regions
RS59413B1 (en) 2011-02-25 2019-11-29 Regeneron Pharma Adam6 mice
DK2739740T3 (en) 2011-08-05 2019-12-09 Regeneron Pharma Universal, humanized light chain mice
CA2850041A1 (en) 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2664473C2 (en) 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. Non-human animals expressing ph-sensitive immunoglobulin sequences
MX355105B (en) 2013-02-20 2018-04-05 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences.

Also Published As

Publication number Publication date
SG11201405165UA (en) 2014-10-30
CN104302169A (en) 2015-01-21
BR112014022850A2 (en) 2017-07-18
US20140329711A1 (en) 2014-11-06
RU2644684C2 (en) 2018-02-13
PL2883449T3 (en) 2018-07-31
JP6574802B2 (en) 2019-09-11
IL244097A (en) 2017-06-29
HRP20180682T1 (en) 2018-06-01
RS57118B1 (en) 2018-06-29
LT2825036T (en) 2018-07-10
JP2017104139A (en) 2017-06-15
PT2883449T (en) 2018-05-07
US20160311899A1 (en) 2016-10-27
US20130247234A1 (en) 2013-09-19
EP2883449B1 (en) 2018-02-07
AU2018203713A1 (en) 2018-06-21
CN107827979A (en) 2018-03-23
DK2883449T3 (en) 2018-04-23
MX355732B (en) 2018-04-27
JP2019071910A (en) 2019-05-16
ES2679369T3 (en) 2018-08-24
HUE037659T2 (en) 2018-09-28
EP3348140A3 (en) 2018-10-03
WO2013138680A4 (en) 2013-11-07
US9422370B2 (en) 2016-08-23
ES2665793T3 (en) 2018-04-27
RS57414B1 (en) 2018-09-28
SG10201607689PA (en) 2016-10-28
EP2825036B1 (en) 2018-05-02
MX2014011051A (en) 2015-04-08
WO2013138680A1 (en) 2013-09-19
PL2825036T3 (en) 2018-10-31
JP6185978B2 (en) 2017-08-23
US9334334B2 (en) 2016-05-10
IL234355A (en) 2018-07-31
EP3348140A2 (en) 2018-07-18
DK2825036T3 (en) 2018-07-16
RU2017135754A (en) 2019-02-08
KR20140135193A (en) 2014-11-25
HUE039573T2 (en) 2019-01-28
EP2883449A1 (en) 2015-06-17
CN107840890A (en) 2018-03-27
SI2883449T1 (en) 2018-05-31
PT2825036T (en) 2018-07-26
CA2865643A1 (en) 2013-09-19
IL244097D0 (en) 2016-04-21
AU2016202323B2 (en) 2018-03-01
RU2014141537A (en) 2016-05-20
CN104302169B (en) 2017-11-17
CY1120491T1 (en) 2019-07-10
AU2013204579B2 (en) 2016-01-14
HRP20181228T1 (en) 2018-10-05
LT2883449T (en) 2018-05-10
NZ629639A (en) 2017-03-31
HK1200273A1 (en) 2015-08-07
HK1205642A1 (en) 2015-12-24
EP2825036A1 (en) 2015-01-21
CY1120599T1 (en) 2019-12-11
AU2013204579A1 (en) 2013-10-03
SI2825036T1 (en) 2018-08-31
JP2015510767A (en) 2015-04-13
AU2016202323A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
AP201407810A0 (en) Imidazopyrrolidinone compounds
GB201304182D0 (en) No details
IL237341D0 (en) Pro-neurogenic compounds
IL254716D0 (en) Zinc-lysine complex
GB201214750D0 (en) Compounds
HK1215183A1 (en) Protein-polymer-drug conjugates --
EP2836211A4 (en) Novel methods
IL235986A (en) Tetrahydropyrazolopyrimidine compounds
HK1208025A1 (en) Aminoimidazopyridazines
GB201215357D0 (en) Compounds
IL253775D0 (en) נוגדנים בעלי שרשרת קלה מהונדסת היסטידין ובעלי חיים לא אנושיים שעברו שינוי גנטי להכנתם
GB201209138D0 (en) Compounds
EP2754580A4 (en) Dumptruck
GB201217018D0 (en) Methods
GB201403961D0 (en) No details
PL2825528T3 (en) Substituted pyrrolidine-2-carboxamides
EP2934531A4 (en) Combination
EP2846787A4 (en) New methods
EP2887803A4 (en) Pro-neurogenic compounds
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
HK1206726A1 (en) Imidazotriazinone compounds
GB201204125D0 (en) Compounds
IL236295A (en) Indanesulfamide derivative
EP2912485A4 (en) Positioning
GB201420527D0 (en) Electrical-wire-protecting member